Ovarian Cancer
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GCT1184-02)
- Details
ClinicalTrials.gov ID:
NCT06619236
Diagnosis Type:
NA
USOR Number:
- Address
,
P: